Lysosomotropic agents as HCV entry inhibitors
- PMID: 21481279
- PMCID: PMC3090357
- DOI: 10.1186/1743-422X-8-163
Lysosomotropic agents as HCV entry inhibitors
Abstract
HCV has two envelop proteins named as E1 and E2 which play an important role in cell entry through two main pathways: direct fusion at the plasma membrane and receptor-mediated endocytosis. Fusion of the HCV envelope proteins is triggered by low pH within the endosome. Lysosomotropic agents (LA) such as Chloroquine and Ammonium chloride (NH₄Cl) are the weak bases and penetrate in lysosome as protonated form and increase the intracellular pH. To investigate the antiviral effect of LA (Chloroquine and NH₄Cl) on pH dependent endocytosis, HCV pseudoparticles (HCVpp) of 1a and 3a genotype were produced and used to infect liver cells. The toxicological effects of Chloroquine and NH₄Cl were tested in liver cells through MTT cell proliferation assay. For antiviral screening of Chloroquine and NH₄Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH₄Cl and there luciferase activity was determined by using a luminometer. The results demonstrated that Chloroquine and NH₄Cl showed more than 50% reduction of virus infectivity at 50 μM and 10 mM concentrations respectively. These results suggest that inhibition of HCV at fusion step by increasing the lysosomal pH will be better option to treat chronic HCV.
Figures




Similar articles
-
Inhibition of hepatitis C virus 3a genotype entry through Glanthus Nivalis Agglutinin.Virol J. 2011 May 20;8:248. doi: 10.1186/1743-422X-8-248. Virol J. 2011. PMID: 21599979 Free PMC article.
-
A novel small molecule inhibitor of hepatitis C virus entry.PLoS Pathog. 2010 Sep 2;6(9):e1001086. doi: 10.1371/journal.ppat.1001086. PLoS Pathog. 2010. PMID: 20838466 Free PMC article.
-
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.Gut. 2014 Jul;63(7):1137-49. doi: 10.1136/gutjnl-2012-304299. Gut. 2014. PMID: 23903236
-
[Research on hepatitis C virus entry inhibitor].Bing Du Xue Bao. 2015 Jan;31(1):97-105. Bing Du Xue Bao. 2015. PMID: 25997338 Review. Chinese.
-
Hepatitis C virus entry.Curr Top Microbiol Immunol. 2013;369:87-112. doi: 10.1007/978-3-642-27340-7_4. Curr Top Microbiol Immunol. 2013. PMID: 23463198 Review.
Cited by
-
Exogenous loading of extracellular vesicles, virus-like particles, and lentiviral vectors with supercharged proteins.Commun Biol. 2022 May 19;5(1):485. doi: 10.1038/s42003-022-03440-7. Commun Biol. 2022. PMID: 35590035 Free PMC article.
-
Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293. doi: 10.1002/prp2.293. eCollection 2017 Feb. Pharmacol Res Perspect. 2017. PMID: 28596841 Free PMC article. Review.
-
Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.Ther Adv Musculoskelet Dis. 2020 Sep 3;12:1759720X20947296. doi: 10.1177/1759720X20947296. eCollection 2020. Ther Adv Musculoskelet Dis. 2020. PMID: 32952617 Free PMC article.
-
The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA.Mol Ther. 2016 Dec;24(12):2100-2108. doi: 10.1038/mt.2016.179. Epub 2016 Sep 16. Mol Ther. 2016. PMID: 27633442 Free PMC article.
-
Hydroxychloroquine in rheumatic autoimmune disorders and beyond.EMBO Mol Med. 2020 Aug 7;12(8):e12476. doi: 10.15252/emmm.202012476. Epub 2020 Jul 26. EMBO Mol Med. 2020. PMID: 32715647 Free PMC article. Review.
References
-
- Nousbaum JB, Pol S, Nalpas B. Group atCS. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med. 1995;122:161–168. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical